

A Primary Care MD Talks About Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) References

- Abenavoli L, Gambardella ML, Scarlata GGM, Lenci I, Baiocchi L, Luzzo F. The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation. *Medicina (Kaunas)*. 2024 Mar 29;60(4):563. doi: 10.3390/medicina60040563. PMID: 38674209; PMCID: PMC11051743.
- Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. *J Obes Metab Syndr*. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13. PMID: 37700494; PMCID: PMC10583766.
- Chen V, Tincopa M. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [Internet]. Ann Arbor (MI): University of Michigan Medicine; revised 2023 Nov [cited 2024 Apr 29]. Available From: <https://www.med.umich.edu/1libr/Hepatology/NAFLDDiseaseInfo#:~:text=MASLD%20used%20to%20be%20called,hear%20people%20call%20it%20NAFLD.&text=People%20with%20MASLD%20generally%20have,fat%20buildup%20in%20the%20liver.>
- Chopra S, Lai M. Management of metabolic dysfunction-associated steatotic liver disease (nonalcoholic fatty liver disease) in adults. In: UpToDate, Lindor KD (Ed), Wolters Kluwer. (Accessed on April 29, 2024). Available from: https://www.uptodate.com/contents/management-of-metabolic-dysfunction-associated-steatotic-liver-disease-nonalcoholic-fatty-liver-disease-in-adults?search=Management%20of%20metabolic%20dysfunction-associated%20steatotic%20liver%20disease%20%28nonalcoholic%20fatty%20liver%20disease%29%20in%20adults.&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#references.
- Croci I, Coombes JS, Bucher Sandbakk S, et al. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. *The HUNT Study, Prog Cardiovasc Dis*. 2019 Mar-Apr;62(2):127-134. doi: 10.1016/j.pcad.2019.01.005. Epub 2019 Feb 21. PMID: 30796942.
- Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010. PMID: 35569886.
- Esckridge W, Cryer DR, Schattenberg JM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. *J Clin Med*. 2023 Sep 26;12(19):6216. doi: 10.3390/jcm12196216. PMID: 37834859; PMCID: PMC10573476.
- Fahim SM, Tice JA, Suh K, et al. Resmetirom for nonalcoholic steatohepatitis. *J Manag Care Spec Pharm*. 2023 Oct;29(10):1169-1172. doi: 10.18553/jmcp.2023.29.10.1169. PMID: 37776115; PMCID: PMC10541630.
- Fatty Liver Disease: A Family Issue [Internet]. Pittsburgh (PA): Nash kNOWledge; 2021 [cited 2024 May 6]. Available from: <https://drive.google.com/file/d/1a5acKclKrEyhoxKHzc672JRk2JMRudm/view>.
- Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2023 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. PMID: 31727409.
- Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. *N Engl J Med*. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. PMID: 38324483.
- Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med*. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16. PMID: 37845512; PMCID: PMC10667098.
- Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. *J Hepatol*. 2023 Dec;79(6):1524-1541. doi: 10.1016/j.jhep.2023.08.030. Epub 2023 Sep 18. PMID: 37730124.
- Jiang Y, Wu L, Zhu X, Bian H, Gao X, Xia M. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics. *Lipids Health Dis*. 2024 Apr 2;23(1):95. doi: 10.1186/s12944-024-02092-2. PMID: 38566209; PMCID: PMC10985930.
- Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Nouredin M. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. *Clin Gastroenterol Hepatol*. 2024 Jun;22(6):1330-1332.e4. doi: 10.1016/j.cgh.2023.11.003. Epub 2023 Nov 8. PMID: 37949334.
- Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. *Hepatology*. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9. PMID: 38445559.
- Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol*. 2012 Jul;57(1):157-66. doi: 10.1016/j.jhep.2012.02.023. Epub 2012 Mar 10. PMID: 22414768.
- Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. *Metabolism*. 2024 May;154:155835. doi: 10.1016/j.metabol.2024.155835. Epub 2024 Mar 19. PMID: 38508373.
- Kwanten WJ. Diet and non-alcoholic fatty liver disease, a short narrative review. *Acta Gastroenterol Belg*. 2023 Apr-Jun;86(2):306-310. doi: 10.51821/86.2.11547. PMID: 37428163.
- Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. *Eur J Intern Med*. 2024 Apr;122:3-10. doi: 10.1016/j.ejim.2023.11.005. Epub 2023 Nov 7. PMID: 37940495.
- McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol*. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11. PMID: 27725647; PMCID: PMC5418560.
- Montemayor S, García S, Monserrat-Mesquida M, Tur JA, Bouzas C. Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review. *Nutrients*. 2023 Sep 14;15(18):3987. doi: 10.3390/nu15183987. PMID: 37764771; PMCID: PMC10534915.
- Moreira RO, Valerio CM, Villela-Nogueira CA, et al. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). *Arch Endocrinol Metab*. 2023 Nov 27;67(6):e230123. doi: 10.20945/2359-4292-2023-0123. PMID: 38048417.
- Moving Matters for My Health [Internet]. Centers for Disease Control and Prevention; 2024 Apr 12 [cited 2024 June 28]. Available from: <https://www.cdc.gov/moving-matters/about/index.html>.
- Ni Than N. Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A General Overview and Approach in Clinical Practice. *Med Res Arch*. 2023 Nov;11(11). doi: 10.18103/mra.v11i11.4610. Epub 2023 Nov 29.
- Primary Care MASLD* Toolkit [Internet]. Austin (TX): American Association of Nurse Practitioners; [cited 2024 June 13]. Available from: https://storage.aanp.org/www/documents/education/NASH_Tool_2.pdf.
- REZDIFFRA (resmetirom) [Highlights of prescribing information]. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc. Approved March 2024. https://www.madrigalpharma.com/wp-content/uploads/2024/06/NDA-217785-REZDIFFRA-PI_14Mar2024_final-revised-clean-SPLPI.pdf. Accessed May 3, 2024.
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17. PMID: 36727674; PMCID: PMC10735173.
- Unalp-Arida A, Ruhl CE. Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. *Dig Dis Sci*. 2023 Apr;68(4):1237-1252. doi: 10.1007/s10620-022-07707-1. Epub 2022 Sep 29. PMID: 36173583; PMCID: PMC9521005.

Writing Group

Writing Group (and Disclosures for Pharmaceutical Relationships): Sarah Ball, PharmD (none), Sandra Counts, PharmD (none), Nancy Hahn, PharmD (none), Jenna McCauley, PhD (none), William Moran, MD (none), Megan Pruitt, PharmD (none), Andrew Schreiner, MD (Novo Nordisk [not related to content]), Lauren Linder Wier, PharmD (none).

Acknowledgements: Chloe Bays assisted with concept design and review. The MUSC Drug Information Center assisted with background research.